TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20174905
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (O) 20 mg once daily
Study: 20174905
Drug: Amlodipine (A)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (A) 10 mg once daily
Study: 18344941
Drug: ATG (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (9 mg/kg ATG Fresenius S)
Study: 17162992
Drug: Home CPAP
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home CPAP titration (3 nights)
Study: 17162992
Drug: In-laboratory CPAP
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-laboratory CPAP titration (1 night)
Study: 11071801
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (persistent medical treatment)
Study: 6381006
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) using the Mill-Hill Infuser
Study: 6381006
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (MI) using the Medi-Jector
Study: 29332645
Drug: Pre-meal administration
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-meal administration of Rifampicin
Study: 29332645
Drug: Post-meal administration
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-meal administration of Rifampicin
Study: 29332645
Drug: Pre-meal administration
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-meal administration of Pyrazinamide
Study: 29332645
Drug: Post-meal administration
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-meal administration of Pyrazinamide
Study: 28040121
Drug: sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual misoprostol 400 μg
Study: 28040121
Drug: intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous oxytocin 20 units
Study: 24443547
Drug: NVP-based combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP-based combination antiretroviral therapy (cART)
Study: 21414137
Drug: Maxillary 3-implant
Normalized name: ARTEMISIA CAPILLARIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary 3-implant overdentures with splinted attachment system
Study: 21414137
Drug: Maxillary 3-implant
Normalized name: ARTEMISIA CAPILLARIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary 3-implant overdentures with unsplinted attachment system
Study: 21414137
Drug: Conventional maxillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional maxillary dentures (pre-treatment)
Study: 21414137
Drug: Maxillary 3-implant
Normalized name: ARTEMISIA CAPILLARIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary 3-implant overdentures (after 1 year)
Study: 21414137
Drug: Maxillary 3-implant
Normalized name: ARTEMISIA CAPILLARIS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary 3-implant overdentures (after 2 years)
Study: 18158878
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment plus Lactobacillus casei strain Shirota
Study: 18158878
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment alone (control)
Study: 11791032
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg) followed by Losartan (50 mg) or Amlodipine (5 mg)
Study: 25170037
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative therapy (OMTh)
Study: 25616647
Drug: Nimotuzumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab 400 mg weekly added to standard radiochemotherapy followed by 400 mg biweekly after twelve weeks
Study: 19299777
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg tablet
Study: 17719327
Drug: GLP-1 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (1.5 pmol/kg/min) as a continuous infusion beginning 12 hours before CABG and continuing for 48 hours
Study: 17719327
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy at the discretion of the surgeon
Study: 17719327
Drug: GLP-1 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (1.5 pmol/kg/min) as a continuous infusion
Study: 14744921
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg twice daily for 4 weeks
Study: 14744921
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg/d for 4 weeks
Study: 14744921
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg twice daily at peak
Study: 14744921
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg/d at peak
Study: 14744921
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg twice daily for 24 hours
Study: 14744921
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg/d for 24 hours
Study: 11799264
Drug: Increased dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dialysis treatment time by 2 h and reduced dry weight (group 1)
Study: 11799264
Drug: Increased dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dialysis treatment time by 2 h without changing dry weight (group 2)
Study: 11799264
Drug: Reduced dry
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dry weight without changing dialysis treatment time (group 3)
Study: 7975783
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha-2a (IFN alpha-2a) at a dosage of 3 x 3 million units per week for 1 year
Study: 2596943
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention strategy (monthly mailed informational packets and monthly to quarterly telephone contacts)
Study: 1122924
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion infusion
Study: 26167618
Drug: ART within
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART within 4 weeks of starting TB treatment (Arm-1)
Study: 26167618
Drug: ART after
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART after the intensive phase of TB treatment (Arm-2)
Study: 26167618
Drug: ART after
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART after completing TB treatment (Arm-3)
Study: 9562232
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MPA) 2 x 1 g/day during peritoneal dialysis
Study: 9562232
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MPA) 2 x 1 g/day without peritoneal dialysis
Study: 2440455
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midodrin hydrochloride administered intravenously
Study: 2440455
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midodrin hydrochloride as drinking solution
Study: 2440455
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midodrin hydrochloride as tablet (Gutron)
Study: 24860256
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and sevoflurane 1.0 MAC
Study: 24860256
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and rocuronium 0.45 mg kg(‐1)
Study: 22863096
Drug: Probiotic cheese
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cheese containing Lactobacillus plantarum Tensia at a concentration of 9.6 log cfu/g for 30 consecutive days.
Study: 22863096
Drug: Probiotic cheese
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cheese with a daily dose of 10.3 or 8.17 log cfu/serving for 3 weeks.
Study: 22863096
Drug: Regular semihard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular semihard Edam-type cheese with probiotic additive at a daily dose of 50g or in excess (100g) and with a probiotic daily dose of 10 log cfu for 3 weeks.
Study: 18672532
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (8-week on/8-week off)
Study: 14625133
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mixture (25% insulin lispro and 75% NPL) plus metformin (Mix25+M)
Study: 14625133
Drug: Glibenclamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide plus metformin (G+M)
Study: 14625133
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mixture (Mix25+M)
Study: 8370356
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nisoldipine) administered before or during ischaemia
Study: 3523396
Drug: Meperidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (150 mg)
Study: 3523396
Drug: Fluradoline (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluradoline (450 mg)
Study: 29436172
Drug: 100 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/wk testosterone cypionate
Study: 29436172
Drug: 250 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/wk testosterone cypionate
Study: 29436172
Drug: 500 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/wk testosterone cypionate
Study: 27510295
Drug: Methylprednisolone 500
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1 mg/kg/day
Study: 27510295
Drug: 100% normobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% normobaric oxygen with mask, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
Study: 20846257
Drug: Oral 600
Normalized name: tolmetin
DrugBank: Tolmetin (DB00500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 600 µg misoprostol
Study: 20846257
Drug: Sublingual 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 600 µg misoprostol
Study: 18201934
Drug: KADIAN (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN (morphine sulfate extended-release) with 240 mL 40% alcohol
Study: 18201934
Drug: KADIAN (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN (morphine sulfate extended-release) with water (fasted)
Study: 18201934
Drug: KADIAN (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN (morphine sulfate extended-release) with alcohol under fasted or fed conditions
Study: 16620710
Drug: Preoperative hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC)
Study: 16620710
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (radical surgery and general venous chemotherapy)
Study: 10967371
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily) + Folic Acid (500 microg)
Study: 8641579
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive chemotherapy during remission induction
Study: 22992267
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 900 mg capsules thrice daily (total daily dose 2.7 g per day)
Study: 22992267
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules thrice daily
Study: 18358737
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² administered every 21 days
Study: 11334901
Drug: Oral estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogens
Study: 14673604
Drug: Carrot meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot meal (188 g carrot purée providing 30 mg beta-carotene)
Study: 14673604
Drug: Tomato meal
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato meal (61 g tomato purée providing 30 mg lycopene)
Study: 14673604
Drug: Spinach meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach meal (260 g cooked chopped spinach providing 30 mg lutein)
Study: 9342767
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of hypericum extract
Study: 9342767
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy combined with hypericum
Study: 1469927
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg twice daily for 10 days)
Study: 1469927
Drug: Trimethoprim-sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily for 10 days)
Study: 23517838
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control subjects)
Study: 19034108
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bupivacaine, 0.25% (TEA group)
Study: 19034108
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline (control group)
Study: 9124833
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg biweekly
Study: 9124833
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg biweekly with Rifampin
Study: 9124833
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg biweekly without Rifampin
Study: 9124833
Drug: Dapsone with
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone with high bilirubin levels (> 1.2 mg/dl)
Study: 9124833
Drug: Dapsone with
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone with normal bilirubin levels (0.7 mg/dl)
Study: 1559334
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Study: 1559334
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Study: 1559334
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and vaginal)
Study: 30345939
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education curriculum (implemented twice per week for 6 weeks)
Study: 29325289
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg/d for 208 weeks
Study: 29325289
Drug: Telbivudine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 0.6 g/d for 208 weeks
Study: 23490224
Drug: BEA2180 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEA2180 (50, 100 or 200 μg)
Study: 23490224
Drug: Tiotropium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (5 μg)
Study: 23490224
Drug: BEA2180 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEA2180 (200 μg)
Study: 23490224
Drug: BEA2180 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEA2180 (50 and 200 μg)
Study: 9146850
Drug: Prednisolone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1.5 mg kg‐1)
Study: 7964943
Drug: UFT 350
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 350 mg/m2/d plus oral leucovorin 150 mg/d
Study: 7964943
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/m2/d plus oral leucovorin 150 mg/d
Study: 3596338
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg at 2300 h
Study: 3596338
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg at 2300 h
Study: 3596338
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg at 2300 h
Study: 3596338
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bd (0800 h and 2300 h)
Study: 3596338
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg at 1800 h
Study: 3596338
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg at 1800 h
Study: 3596338
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at 1800 h
Study: 29212965
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day pitavastatin plus 10 mg/day ezetimibe
Study: 27755389
Drug: Sequential nephron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential nephron blockade
Study: 27755389
Drug: Sequential renin-angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential renin-angiotensin system blockade
Study: 14600517
Drug: High-dose multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multiple micronutrient supplementation
Study: 10825334
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV (Group O4)
Study: 10825334
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg IV (Group O8)
Study: 31892352
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h(‐ 1) for a total of 1 h
Study: 31892352
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at increasing rates
Study: 31892352
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 IU h(‐ 1) infusion)
Study: 24929133
Drug: Multi-component integrated
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component integrated control strategy including bovine vaccination using a heterologous 'prime-boost' delivery platform based on the SjCTPI vaccine.
Study: 24929133
Drug: Mass human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mass human chemotherapy and mollusciciding as part of the integrated strategy.
Study: 9491040
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl, 15 to 20 microgram/kg
Study: 30180236
Drug: L-arginine mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine mouthwash
Study: 30180236
Drug: D-panthenol gel
Normalized name: D-PANTHENOL
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-panthenol gel
Study: 23579036
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel
Study: 30180236
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of corn oil gel (placebo)
Study: 30180236
Drug: Triester glycerol
Normalized name: Triester Glycerol Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triester glycerol oxide gel
Study: 24842806
Drug: Transient ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient ovarian suspension
Study: 16060401
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg gabapentin (100 mg, twice daily)
Study: 16060401
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg gabapentin (100 mg, four times daily)
Study: 16060401
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg gabapentin (200 mg, three times daily)
Study: 12192247
Drug: anti‐BLyS monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐BLyS monoclonal antibody
Study: 12192247
Drug: anti‐CD40L monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐CD40L monoclonal antibody
Study: 7477802
Drug: Combined cognitive-behavioral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-behavioral, nutritional and antidepressant therapy (5 with amineptine and 10 with fluvoxamine)
Study: 7036932
Drug: Clofibrate (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (single oral dose)
Study: 31480678
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group treatment (CBT) with development-specific topics for adolescents and young adults (YOUTH)
Study: 25677397
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with fluoxetine 20-40 mg/day plus interpersonal psychotherapy adapted to BPD (IPT-BPD) for 32 weeks